INVO Bioscience prelim Q4 revenue $270-280K, up 15-19% QoQ; signs Wisconsin clinic acquisition

INVO Fertility, Inc.

Q4 2022 revenue expected $270K-$280K, up 15-19% from Q3 2022's $235K.
Full year 2022 revenue expected $815K-$825K, up 38-40% YoY excluding $3.6M deferred revenue from Ferring.
Gross operating expenses for FY2022 expected $10.5M-$11.0M, up 14-19% YoY.
Signed binding purchase agreement for Wisconsin Fertility Institute (clinic generated ~$5.5M revenue, $1.9M net income in trailing 12 months).
Closed registered direct offering for ~$3M gross proceeds in March 2023; 10-K filing extended to April 15, 2023.

item 2.02 item 7.01 item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.96

INVO Fertility, Inc. reported preliminary financial results for fourth quarter and year ended December 31, 2022.

Period: fourth quarter and year ended December 31, 2022
Result: preliminary results

Exact text from the filing

On March 30, 2023, INVO Bioscience, Inc. (the "Company") issued a press release announcing preliminary financial results for the fourth quarter and the year ended December 31, 2022.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-009849

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.